Compound A Uptake and Metabolism to Mercapturic Acids and 3,3,3-Trifluoro-2-fluoromethoxypropanoic Acid during Low-flow Sevoflurane Anesthesia
- 1 November 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 91 (5) , 1267
- https://doi.org/10.1097/00000542-199911000-00017
Abstract
Background: Sevoflurane is degraded during low-flow anesthesia to fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A"), which causes renal necrosis in rats but is not known to cause nephrotoxicity in surgical patients. Compound A is metabolized to glutathione S-conjugates and then to cysteine S-conjugates, which are N-acetylated to mercapturic acids (detoxication pathway), or metabolized by renal beta-lyase to reactive intermediates (toxification pathway) and excreted as 3,3,3-trifluoro-2-fluoromethoxypropanoic acid. This investigation quantified compound A metabolites in urine after low-flow sevoflurane administration, to assess relative flux via these two pathways. Methods: Patients (n = 21) with normal renal function underwent low-flow (11 min) sevoflurane anesthesia designed to maximize compound A formation. Inspiratory, expiratory, and alveolar compound A concentrations were quantified. Urine mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid concentrations were measured by gas chromatography and mass spectrometry. Results: Sevoflurane exposure was 3.7 +/- 2.0 MAC-h. Inspired compound A maximum was 29 +/- 14 ppm; area under the inspired concentration versus time curve (AUCinsp) was 78 +/- 58 ppm x h. Compound A dose, calculated from pulmonary uptake, was 0.39 +/- 0.35 mmol (4.8 +/- 4.0 micromol/kg) and correlated with AUCinsp (r2 = 0.84, P < 0.001). Mercapturic acids excretion was complete after 2 days, whereas 3,3,3-trifluoro-2-fluoromethoxypropanoic acid excretion continued for 3 days in some patients. Total (3-day) mercapturates and fluoromethoxypropanoic acid excretion was 95 +/- 49 and 294 +/- 416 micromol, respectively (1.2 +/- 0.6 and 3.6 +/- 5.0 micromol/kg). Conclusion: Compound A doses during 3.7 MAC-h, low-flow sevoflurane administration in humans are substantially less than the threshold for renal toxicity in rats (200 micromol/kg). Compound A metabolites quantification may provide a biomarker for compound A exposure and relative metabolism via toxification and detoxication pathways. Compared with previous investigations, relative metabolic flux (fluoromethoxypropanoic acid/mercapturates) through the toxification pathway was sixfold greater in rats than in humans. Species differences in dose and metabolism may influence compound A renal effects.Keywords
This publication has 38 references indexed in Scilit:
- RENAL TOXICITY OF COMPOUND A PLUS SEVOFLURANE COMPARED WITH ISOFLURANE IN NON-HUMAN PRIMATESAnesthesiology, 1998
- Role of the Renal Cysteine Conjugate β-Lyase Pathway in Inhaled Compound A Nephrotoxicity in RatsAnesthesiology, 1998
- GLUTATHIONE-DEPENDENT BIOACTIVATION OF HALOALKENESAnnual Review of Pharmacology and Toxicology, 1998
- Dehydration of Baralyme[registered sign] Increases Compound A Resulting from Sevoflurane Degradation in a Standard Anesthetic Circuit Used to Anesthetize SwineAnesthesia & Analgesia, 1997
- Inhalation Toxicity Study of a Haloalkene Degradant of Sevoflurane, Compound A (PIFE), in Sprague-Dawley RatsAnesthesiology, 1995
- Plasma Inorganic Fluoride and Intracircuit Degradation Product Concentrations in Long-Duration, Low-Flow Sevoflurane AnesthesiaAnesthesia & Analgesia, 1994
- Toxicity of Compound A in RatsAnesthesiology, 1994
- Closed-circuit Anesthesia with Sevoflurane in Humans Effects on Renal and Hepatic Function and Concentrations of Breakdown Products with Soda Lime in the CircuitAnesthesiology, 1994
- Reaction of Sevoflurane and Its Degradation Products with Soda LimeAnesthesiology, 1992
- Quantification of the Degradation Products of Sevoflurane in Two CO2 Absorbants during Low-flow Anesthesia in Surgical PatientsAnesthesiology, 1992